Sequana Medical NV (SEQUA) - Total Assets
Based on the latest financial reports, Sequana Medical NV (SEQUA) holds total assets worth €14.57 Million EUR (≈ $17.04 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Sequana Medical NV to assess how comfortably operating cash covers total debt obligations.
Sequana Medical NV - Total Assets Trend (2014–2024)
This chart illustrates how Sequana Medical NV's total assets have evolved over time, based on quarterly financial data. See Sequana Medical NV (SEQUA) shareholders funds for net asset value and shareholders' equity analysis.
Sequana Medical NV - Asset Composition Analysis
Current Asset Composition (December 2024)
Sequana Medical NV's total assets of €14.57 Million consist of 64.5% current assets and 35.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 38.3% |
| Accounts Receivable | €301.18K | 3.0% |
| Inventory | €2.05 Million | 20.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Sequana Medical NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SEQUA stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sequana Medical NV's current assets represent 64.5% of total assets in 2024, a decrease from 96.9% in 2014.
- Cash Position: Cash and equivalents constituted 38.3% of total assets in 2024, down from 67.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 20.6% of total assets.
Sequana Medical NV Competitors by Total Assets
Key competitors of Sequana Medical NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Oncosil Medical Ltd
AU:OSL
|
Australia | AU$7.13 Million |
Sequana Medical NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.20 | 0.41 | 2.19 |
| Quick Ratio | 0.16 | 0.29 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-41.58 Million | €-10.31 Million | €9.53 Million |
Sequana Medical NV - Advanced Valuation Insights
This section examines the relationship between Sequana Medical NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.22 |
| Latest Market Cap to Assets Ratio | 4.80 |
| Asset Growth Rate (YoY) | -1.6% |
| Total Assets | €9.94 Million |
| Market Capitalization | $47.76 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sequana Medical NV's assets at a significant premium (4.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Sequana Medical NV's assets decreased by 1.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sequana Medical NV (2014–2024)
The table below shows the annual total assets of Sequana Medical NV from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €9.94 Million ≈ $11.63 Million |
-1.55% |
| 2023-12-31 | €10.10 Million ≈ $11.81 Million |
-61.19% |
| 2022-12-31 | €26.03 Million ≈ $30.43 Million |
+76.98% |
| 2021-12-31 | €14.71 Million ≈ $17.19 Million |
+3.46% |
| 2020-12-31 | €14.21 Million ≈ $16.62 Million |
+52.01% |
| 2019-12-31 | €9.35 Million ≈ $10.93 Million |
+179.85% |
| 2018-12-31 | €3.34 Million ≈ $3.91 Million |
-5.06% |
| 2017-12-31 | €3.52 Million ≈ $4.11 Million |
-7.57% |
| 2016-12-31 | €3.81 Million ≈ $4.45 Million |
-18.67% |
| 2015-12-31 | €4.68 Million ≈ $5.47 Million |
-22.52% |
| 2014-12-31 | €6.04 Million ≈ $7.06 Million |
-- |
About Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more